161.53
-2.28 (-1.39%)
| Penutupan Terdahulu | 163.81 |
| Jumlah Dagangan | 806,466 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.67 |
| Harga / Jualan (P/S) | 15.49 |
| Harga / Buku (P/B) | 14.16 |
| Julat 52 Minggu |
| Margin Keuntungan | -30.57% |
| Margin Operasi (TTM) | -19.39% |
| EPS Cair (TTM) | -2.27 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.09% |
| Nisbah Semasa (MRQ) | 6.49 |
| Aliran Tunai Operasi (OCF TTM) | -45.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.66 M |
| Pulangan Atas Aset (ROA TTM) | -6.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Glaukos Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.25 |
|
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.33% |
| % Dimiliki oleh Institusi | 101.71% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| NAVRATIL TOMAS | - | 163.47 | -1,457 | -238,176 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,457 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -238,176 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 163.47 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| NAVRATIL TOMAS | Pegawai | 16 Sep 2026 | Jual automatik (-) | 1,457 | 163.47 | 238,176 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |